chart abstraction

OTHER4 trials

Sponsors

Duke University, SWOG Cancer Research Network, University of Washington

Conditions

Advanced Malignant Solid NeoplasmBreast CancerMalignant Neoplasm in the Head and NeckMetastatic Malignant Neoplasm in the Head and NeckMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRenal Cell Carcinoma

Phase 1

Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes

WithdrawnNCT05490381

University of WashingtonMalignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck

Start: 2023-12-21End: 2025-01-31Updated: 2023-12-12

Unknown Phase

HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program

CompletedNCT02616133

Duke UniversityBreast Cancer

Start: 2016-01-31End: 2017-03-31Updated: 2017-07-02

NCCN Renal Cell Registry

CompletedNCT02677337

Duke UniversityRenal Cell Carcinoma

Start: 2016-03-31End: 2016-12-31Updated: 2017-02-17

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

Active, not recruitingNCT05455606

SWOG Cancer Research NetworkAdvanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm +1

Start: 2022-10-14End: 2027-03-01Updated: 2026-01-22

Related Papers

Successful accrual of a cluster randomized controlled trial (RCT) comparing an educationally enhanced genomic tumor board (EGTB) intervention to usual practice (S2108CD, NCT# 05455606).

Journal of Clinical Oncology2025-05-28

Utilization of genomic tumor testing (GTT) among community oncologists participating in SWOG S2108CD.

JCO Oncology Practice2024-09-30

Mixed-methods analysis of physician genomic confidence in the pre-implementation phase of the cluster randomized trial evaluating genomic tumor boards (SWOG S2108CD, NCT05455606).

JCO Oncology Practice2023-10-26